Integrating elicited patient preferences and clinical trial data in a quantitative model for benefit-risk assessment by Broekhuizen, H. et al.
Integrating elicited patient preferences and clinical trial data 
in a quantitative model for benefit-risk assessment 
Henk Broekhuizen, MSc1; Karin Groothuis-Oudshoorn, PhD1; Brett Hauber, PhD2; J.P. Jansen, PhD3, Maarten IJzerman, PhD1 
 
(1)  University of Twente, dept. Health Technology and Services Research, Enschede, the Netherlands 
(2)  RTI Health Solutions, Research Triangle Park, NC, USA 
(3)  MAPI Group, Boston, MA, USA 
Poster presenter: Henk Broekhuizen, MSc. 
PhD candidate at University of Twente 
 
Contact information: 
h.broekhuizen@utwente.nl 
www.utwente.nl/mb/htsr/Staff/broekhuizen.doc 
Conclusions 
• Elicited patient preferences used to weigh drugs’ 
clinical performance data 
• Integrates uncertainty around patient preferences 
and clinical performance. 
 
Strengths 
• All data structured in one comprehensive model 
• Impact of uncertainty and robustness of decision 
can be checked 
• Visualization of data and uncertainty 
 
Limitations 
• Structural model assumptions 
• Only first order uncertainty considered 
• Inconsistent sampled pairwise comparison matrixes 
for severe adverse events criterion 
 
Future research 
• Regulators’ requirements w.r.t patient preferences 
• Other types of preference studies 
• Using mixed treatment comparison data 
 
 
 
  Benefits   Risks   
  Response Remission Adverse events Severe adverse events 
Median weight (range) 0.62 (0.36 to 0.78) 0.16 (0.07 to 0.34) 0.04 (0.01 to 0.23) 0.19 (0.02 to 0.25) 
Odds ratio (95% CI)         
Dul vs Ven 0.75 (0.52 to 1.08) 0.99 (0.78 to 1.25) 1.06 (0.84 to 1.35) 0.34 (0.03 to 4.18) 
Dul vs Bup 0.96 (0.80 to 1.15) 1.11 (0.91 to 1.34) 1.23 (1.01 to 1.50) 1.65 (0.60 to 4.54) 
Ven vs Bup 1.20 (1.07 to 1.35) 1.12 (0.98 to 1.28) 1.31 (1.14 to 1.50) 0.96 (0.68 to 1.34) 
Partial values (95% CI)         
Duloxetine  0.30 (0.26 to 0.34) 0.34 (0.31 to 0.38) 0.36 (0.33 to 0.40) 0.28 (0.07 to 0.59) 
Venlafaxine  0.39 (0.34 to 0.43) 0.35 (0.32 to 0.38) 0.36 (0.32 to 0.39) 0.45 (0.18 to 0.73) 
Bupropion 0.32 (0.29 to 0.34) 0.31 (0.29 to 0.33) 0.28 (0.26 to 0.31)  0.27 (0.16 to 0.38) 
Table 1: Summary of weights, odds ratios as used in the Monte Carlo simulations, and resulting partial values. The latter were calculated 
with the ratio scale estimation method that utilizes the normalized principal eigenvector of  positive reciprocal pairwise comparison matrixes. 
CI=credibility interval. 
Figure 3: (top row) Estimated densities  of the  weighted benefit performances, weighted risk 
performances and benefit-risk ratios of all drugs, and (bottom row) rank probabilities for weighted 
benefit performances, weighted risk performances and benefit-risk ratios. Green=first rank, 
blue=second rank and red=third rank.  
Figure 4: Example sensitivity graph that shows the sensitivity of Venlafaxine’s benefit-risk ratio to the weights assigned to criteria by patients. The 
vertical grey lines denote the weights’ 95% credibility interval. As expected, its benefit-risk ratio increases with the response criterion and decreases 
with the risk criteria. It is not sensitive to the weight for remission. 
Objectives 
Demonstrate how elicited patient preferences 
can be integrated in a Bayesian framework for 
quantitative benefit-risk assessment. 
Results 
• Identified models: discrete event simulation and multi criteria decision analysis 
(MCDA); found limitation: uncertainty around patient preferences not taken into 
account. 
 
• We therefore developed a Bayesian MCDA model, with 
• Antidepressants used as illustrative case. 
Methods 
We identified models that can be used to integrate preference and 
performance information in quantitative benefit-risk assessment 
models and evaluated if they would be suitable for elicited patient 
preferences. Based on our findings we developed a model. 
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